Skip to content

Construction of a Predictive Model of Gangrenous Cholecystitis Based on Machine Learning

A Real-world Study of Predictive Models of Gangrenous Cholecystitis Based on Machine Learning

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06399081
Enrollment
1006
Registered
2024-05-03
Start date
2023-12-01
Completion date
2024-03-02
Last updated
2024-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gangrenous Cholecystitis

Brief summary

Gangrenous cholecystitis is the most common complication of acute cholecystitis. There is no research using machine learning models to construct predictive diagnostic models for gangrenous cholecystitis.

Detailed description

This study reviewed the clinical data of 2023 cholecystectomy patients admitted to our center between January 1, 2015, and May 31, 2015, it includes demographic, clinical features, laboratory and imaging indexes, and constructs five commonly used Decision Tree, SVM, Random Forest, XGBoost, AdaBoost models, feature subsets are selected by Recursive Feature Elimination with Cross-Validation and the importance of variables in each model, model performance is evaluated by Balanced accuracy, Recall, Precision, F1score, and the Precision-Recall(PR) curve, and the final results are verified by independent external validation sets.

Interventions

OTHERObservational

Observational

Sponsors

National Natural Science Foundation of China
CollaboratorOTHER_GOV
Dalian Medical University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* patients diagnosed with acute cholecystitis or acute exacerbation of chronic cholecystitis in our hospital and receiving complete clinical treatment in our hospital; * performing cholecystectomy; * having complete and searchable clinical data, such as patient's age, surgical records, and hospitalization days.

Exclusion criteria

* previous diagnosis of chronic cholecystitis, this time for elective surgical treatment; * previous diagnosis of acute cholecystitis, ultrasound-guided cholecystectomy after elective laparoscopic cholecystectomy; * concomitant with other acute biliary and pancreatic system-related diseases, such as obstructive jaundice caused by choledochal stones, acute cholangitis, acute pancreatitis, etc.; * exclude patients who combined with other surgery patients such as choledochotomy and lithotripsy, choledochoscopic exploration and lithotripsy, bile-intestinal anastomosis, appendectomy, etc; * those with incomplete data

Design outcomes

Primary

MeasureTime frameDescription
pathological diagnosis of patients with cholecystectomy30 daysCheck the patient's pathological report and whether the pathological description contains phenomena such as full layer ischemic necrosis and ulceration of the gallbladder wall. Diagnose as gangrenous cholecystitis or non-gangrenous cholecystitis.
The predictive performance of diagnostic prediction modelsthrough study completion, an average of 4 monthsThe predictive diagnosis was obtained by the model and each predictive variable, and the metric (Accuracy, Recall, Precision, F1score) of the model was obtained by comparing with the actual pathological diagnosis.

Secondary

MeasureTime frameDescription
D-dimer valuethrough study completion, an average of 4 monthsCorrelation between coagulopathy and patients with gangrenous cholecystitis and non-gangrenous cholecystitis
Fibrinogen value (g/L)through study completion, an average of 4 monthsCorrelation between coagulopathy and patients with gangrenous cholecystitis and non-gangrenous cholecystitis
WBC value (10*9/L)through study completion, an average of 4 monthsCorrelation between WBC and patients with gangrenous cholecystitis and non-gangrenous cholecystitis
Gallbladder wallness (cm)through study completion, an average of 4 monthsCorrelation between Gallbladder wallness and patients with gangrenous cholecystitis and non-gangrenous cholecystitis
BMI (Kg/m2)through study completion, an average of 4 monthsCorrelation between obesity level and patients with gangrenous cholecystitis and non-gangrenous cholecystitis
Alanine transaminase value (ALT, U/L)through study completion, an average of 4 monthsCorrelation between liver function and patients with gangrenous cholecystitis and non-gangrenous cholecystitis

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026